Clinical Trials Arena October 23, 2024
The study will evaluate the company’s Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury.
Nexalin Technology has partnered with the University of California, San Diego, to start a clinical trial evaluating the company’s neurostimulation device, Gen-3 Halo headset, as an at-home treatment for mild traumatic brain injury.
The sham-controlled study will evaluate the effect of the Gen-3 Halo headset on brain activity and symptom relief in veterans with mild traumatic brain injury in virtual clinic settings. The trial is expected to enrol up to 60 participants.
Following the announcement of the trial start, the company’s stock was up by 20.95% as the market closed on 22 October, compared to the previous day.
The current clinical trial...
Today's Sponsors
Today's Sponsor